Feedback / Questions
TP-3654 - Sumitomo Pharma
TP-3654: Launch in Japan for myelofibrosis in FY 2027
(Sumitomo Dainippon)
-
Feb 1, 2024 -
Q3 FY2023 Results
Launch Japan
•
Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
https://www.sumitomo-pharma.com/ir/library/presentation/assets/pdf/eir20240131.pdf
Feb 1, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious